NASDAQ:PRAH - PRA Health Sciences Stock Price, Price Target & More

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) released its quarterly earnings data on Wednesday, April, 25th. The medical research company reported $0.85 earnings per share for the quarter, topping analysts' consensus estimates of $0.84 by $0.01. The medical research company earned $701.80 million during the quarter, compared to analyst estimates of $694.73 million. PRA Health Sciences had a return on equity of 23.06% and a net margin of 4.07%. The business's quarterly revenue was up 43.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.62 earnings per share. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences updated its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share (EPS) guidance of $4.00-4.15 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.12. The company issued revenue guidance of $2.84-2.95 billion, compared to the consensus revenue estimate of $2.91 billion.

10 brokerages have issued 12-month price targets for PRA Health Sciences' stock. Their forecasts range from $86.00 to $104.00. On average, they anticipate PRA Health Sciences' stock price to reach $95.80 in the next year. This suggests that the stock has a possible downside of 3.6%. View Analyst Ratings for PRA Health Sciences.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

PRA Health Sciences saw a decline in short interest in June. As of June 29th, there was short interest totalling 2,898,254 shares, a decline of 31.5% from the June 15th total of 4,229,589 shares. Based on an average daily volume of 1,135,267 shares, the short-interest ratio is presently 2.6 days. Approximately 4.5% of the company's shares are sold short. View PRA Health Sciences' Current Options Chain.

Some companies that are related to PRA Health Sciences include Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Exelixis (EXEL), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), Intrexon (XON), Medpace (MEDP), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX) and Pieris Pharmaceuticals (PIRS).

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Media coverage about PRAH stock has been trending somewhat negative on Wednesday, according to Accern. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. PRA Health Sciences earned a news sentiment score of -0.02 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 45.24 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

PRA Health Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include NN Investment Partners Holdings N.V. (0.48%), Scout Investments Inc. (0.12%), Bellecapital International Ltd. (0.10%), Retirement Systems of Alabama (0.10%), First National Bank of Hutchinson (0.01%) and State of Alaska Department of Revenue (0.01%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, NN Investment Partners Holdings N.V. and Scout Investments Inc.. Company insiders that have sold PRA Health Sciences company stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, Bellecapital International Ltd., First National Bank of Hutchinson, State of Alaska Department of Revenue, Campbell & CO Investment Adviser LLC and Fox Run Management L.L.C.. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $99.42.

PRA Health Sciences has a market capitalization of $6.38 billion and generates $2.26 billion in revenue each year. The medical research company earns $86.92 million in net income (profit) each year or $3.20 on an earnings per share basis. PRA Health Sciences employs 15,800 workers across the globe.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]